DWTX: SEC Form DEF 14A filed by Dogwood Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Historical context for DWTX
Across the 7 sessions after earlier DWTX headlines, the stock closed higher 4 times and lower 3 times, with a median move of 5.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | DWTX | SPY |
|---|---|---|---|
| Feb 2, 2026 | Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 | +5.0% | +0.5% |
| Jan 12, 2026 | Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development | +5.6% | +0.2% |
| Dec 22, 2025 | Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain | -25.0% | +0.6% |
| Dec 2, 2025 | Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 | -2.0% | +0.2% |
| Nov 11, 2025 | Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025 | +1.4% | +0.2% |
| Nov 6, 2025 | Dogwood Therapeutics Reports Third Quarter 2025 Financial Results | -6.5% | -1.1% |
Quantisnow market dataNASDAQ
DWTX
Dogwood Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for DWTX
Full DWTX profile on Quantisnow Follow DWTX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time